Efficacy and Safety of Continuous Glucose Monitoring and Intermittently Scanned Continuous Glucose Monitoring in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis of Interventional Evidence
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Traditional diabetes self-monitoring of blood glucose (SMBG) involves inconvenient finger pricks. Continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems offer CGM, enhancing type 2 diabetes (T2D) management with convenient, comprehensive data. PURPOSE: To assess the benefits and potential harms of CGM and isCGM compared with usual care or SMBG in individuals with T2D. DATA SOURCES: We conducted a comprehensive search of MEDLINE, Embase, the Cochrane Library, Web of Science, and bibliographies up to August 2023. STUDY SELECTION: We analyzed studies meeting these criteria: randomized controlled trials (RCT) with comparison of at least two interventions for ≥8 weeks in T2D patients, including CGM in real-time/retrospective mode, short-/long-term CGM, isCGM, and SMBG, reporting glycemic and relevant data. DATA EXTRACTION: We used a standardized data collection form, extracting details including author, year, study design, baseline characteristics, intervention, and outcomes. DATA SYNTHESIS: We included 26 RCTs (17 CGM and 9 isCGM) involving 2,783 patients with T2D (CGM 632 vs. usual care/SMBG 514 and isCGM 871 vs. usual care/SMBG 766). CGM reduced HbA1c (mean difference -0.19% [95% CI -0.34, -0.04]) and glycemic medication effect score (-0.67 [-1.20 to -0.13]), reduced user satisfaction (-0.54 [-0.98, -0.11]), and increased the risk of adverse events (relative risk [RR] 1.22 [95% CI 1.01, 1.47]). isCGM reduced HbA1c by -0.31% (-0.46, -0.17), increased user satisfaction (0.44 [0.29, 0.59]), improved CGM metrics, and increased the risk of adverse events (RR 1.30 [0.05, 1.62]). Neither CGM nor isCGM had a significant impact on body composition, blood pressure, or lipid levels. LIMITATIONS: Limitations include small samples, single-study outcomes, population variations, and uncertainty for younger adults. Additionally, inclusion of <10 studies for most end points restricted comprehensive analysis, and technological advancements over time need to be considered. CONCLUSIONS: Both CGM and isCGM demonstrated a reduction in HbA1c levels in individuals with T2D, and unlike CGM, isCGM use was associated with improved user satisfaction. The impact of these devices on body composition, blood pressure, and lipid levels remains unclear, while both CGM and isCGM use were associated with increased risk of adverse events.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
1 retracted
Tildesley, H. D., Wright, A. M., Chan, J. H. M., Mazanderani, A. B., Ross, S. A., Tildesley, H. G., Lee, A. M., Tang, T. S., & White, A. S. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.05.006 · Cited by 20
RetractedBias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Rayyan-a web and mobile app for systematic reviews.
Ouzzani, M., Hammady, H., Fedorowicz, Z., & Elmagarmid, A. (2016) · Systematic Reviews · doi:10.1186/s13643-016-0384-4 · Cited by 26,092
Operating characteristics of a rank correlation test for publication bias
Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955
GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables
Guyatt, G., Oxman, A. D., Akl, E. A., Kunz, R., Vist, G., Brozek, J., Norris, S., Falck-Ytter, Y., Glasziou, P., & deBeer, H. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.04.026 · Cited by 10,681
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
Beck, R. W., Riddlesworth, T. D., Ruedy, K., Ahmann, A., Haller, S., Kruger, D., McGill, J. B., Polonsky, W., Price, D., Aronoff, S., et al. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2855 · Cited by 635
Haak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0223-6 · Cited by 623
Self-citation
Cited by
Ji, C., Jiang, T., Liu, L., Zhang, J., & You, L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1571362 · Cited by 87
Patel, P. R., Green, M. M., Tram, J. T., Wang, E., Murphy, M., Abd-Elsayed, A. A., & Chakravarthy, K. V. (2024) · Journal of Pain Research · doi:10.2147/jpr.s494238 · Cited by 67
Tauschmann, M., Cardona‐Hernandez, R., DeSalvo, D. J., Hood, K. K., Лаптев, Д. Н., Olinder, A. L., Wheeler, B. J., & Smart, C. E. (2025) · Hormone Research in Paediatrics · doi:10.1159/000543156 · Cited by 82
Tan, Y. Y., Suan, E., Koh, G. C. H., Suhairi, S. B., & Tyagi, S. (2024) · Archives of Public Health · doi:10.1186/s13690-024-01459-2 · Cited by 35
Aronson, R., Abitbol, A., Bajaj, H. S., Cheng, A. Y. Y., Christopoulos, S., Harris, S. B., Jain, A. B., & Goldenberg, R. M. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70008 · Cited by 33
“Our two search approaches yielded 427 additional papers, 2 new trial records 43,44 and a third trial 45 that was identified from a meta-analysis by Seidu et al. 46 A trial reported by Bergenstal and colleagues 32 that was included in the meta-analysis by Ferreira and colleagues 39 was excluded from our meta-analysis s…”
Rosenfeld, R. M., Grega, M. L., Karlsen, M. C., Dabrh, A. M. A., Aurora, R. N., Bonnet, J. P., Donnell, L., Fitzpatrick, S. L., Frates, E. P., Joy, E. A., et al. (2025) · American Journal of Lifestyle Medicine · doi:10.1177/15598276251325488 · Cited by 54
Perioperative use and accuracy of continuous glucose monitoring: A systematic review
Carlier, L., de Ponthaud, C., Jacqueminet, S., Phan, F., Gaujoux, S., & Amouyal, C. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16583 · Cited by 30
The use of technology in type 2 diabetes and prediabetes: a narrative review
Liarakos, A. L., Lim, J. Z. M., Leelarathna, L., & Wilmot, E. G. (2024) · Diabetologia · doi:10.1007/s00125-024-06203-7 · Cited by 27
“Treatment satisfaction improved with CGM use, especially with newer generation systems, compared with SMBG [13, 17, 20, 21].”
BackgroundMethodRizos, E. C., Markozannes, G., Charitakis, N., Filis, P., Stoimeni, A. E., Nørgaard, K., Ntzani, E. E., & Tsilidis, K. K. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0599 · Cited by 21
Mittal, R., Koutras, N., Maya, J., Lemos, J. R. N., & Hirani, K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1352302 · Cited by 19
The future is here: an overview of technology in diabetes
Mallik, R., Kar, P. S., Mulder, H., & Krook, A. (2024) · Diabetologia · doi:10.1007/s00125-024-06235-z · Cited by 23
“In support of this, studies have shown that CGM use has led to a reduction in HbA 1c [19], increased TIR, reduced time below range (TBR) and reduced glycae-mic variability [20] in individuals with type 2 diabetes.”
Microwave Antenna Sensing for Glucose Monitoring in a Vein Model Mimicking Human Physiology
Zaarour, Y., Arroud, F. E., Fernandez, T., Cano, J. L., Alami, R. E., Mrabet, O. E., Benani, A., Faik, A., & Griguer, H. (2025) · Biosensors · doi:10.3390/bios15050282 · Cited by 20
“While these methods are accurate and widely available, they are also painful, inconvenient, and costly, often leading to poor adherence among patients [5,6].”
Bannuru, R. R., Bellini, N. J., Bergenstal, R. M., Beverly, E. A., Christofides, E. A., Cox, D. J., Ehrhardt, N. M., Fazioli, K., Fischl, A. H., Kerr, D. E., et al. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251384318 · Cited by 20
Thaibah, H. A., Banji, O. J. F., Banji, D., & Alshammari, T. M. (2025) · Pharmaceuticals · doi:10.3390/ph18020214 · Cited by 14
“Advocating clinical guidelines recommending temporary discontinuation during acute illnesses or presurgical periods can mitigate these risks [38,39].”
Zhang, D., Huang, J., Zhang, Y. H., Wei, Z., Long, T., Guo, X., & Li, M. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112907 · Cited by 17
Blood Pressure Time in Target Range and its Impact on Clinical Outcomes
Al-Dalakta, A., Tabaja, C., Motairek, I. K., Hajjar, A. H. E., Agarwal, N., John, J. S., & Laffin, L. J. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02111-9 · Cited by 16
“By mirroring the approach used in diabetes management with continuous glucose monitoring, wearable BP devices would enable precise control and better overall patient outcomes [38–40].”
MethodUse of technology in prediabetes and precision prevention
He, J., Chu, N. H. S., Wan, H., Ling, J., Xue, Y., Leung, K. H. T., Yang, A., Shen, J., & Chow, E. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70057 · Cited by 10
Predictive factors of hypoglycemia in type 2 diabetes: a prospective study using machine learning
Shabestari, M., Mehrabbeik, A., Barbieri, S., Marques-Vidal, P. M., Heshmati-Nasab, P., & Azizi, R. (2025) · Scientific Reports · doi:10.1038/s41598-025-03030-7 · Cited by 15
“Also, CGM has been associated with an increased risk of certain adverse events, including symptoms at the sensor insertion site, infections, headaches, and gastrointestinal issues 28,29 .”
Patient Engagement With Home Blood Pressure Monitoring
Ünlü, O., Zelle, D., Cannon, C. P., Lee, S., McPartlin, M., Subramaniam, S., Tucci, M. R., Oates, M., Figueroa, C., Nichols, H., et al. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2025.5196 · Cited by 12
Continuous peri-operative glucose monitoring in noncardiac surgery: A systematic review
Putzu, A., Grange, E., Schorer, R., Schiffer, E. R. C., & Gariani, K. (2024) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000002095 · Cited by 16
Chang, H., Yeh, K.-C., Huang, Y., & Li, J.-H. (2025) · Nursing Reports · doi:10.3390/nursrep15030094 · Cited by 9
Liarakos, A. L., Randhay, A., & Wilmot, E. G. (2025) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001106 · Cited by 9
Chang, Y., Wang, H., Zhang, X., & Liu, H. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1708301 · Cited by 10
Munshi, M. N., Slyne, C., Adam, A., Krakoff, N., Brabant, H., Savory, M., Maurer, J., & Toschi, E. (2025) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2025.105590 · Cited by 6
Consensus statement on standardizing CGM evaluation metrics in Latin America: an expert approach
Scharf, M., Fériz, K., Yepes, C. A., Contreras, Á., Lequi, L., Sanhueza, D., Krakauer, M., Márquez, E., Ré, M., & Mehta, R. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01851-0 · Cited by 12
Application of Wearable Devices in Diabetes Management
Du, Z., Zhang, F., Ge, Y., Liu, Y., Yu, H., Wang, Y., Dalan, R., & Shen, X. (2025) · Health and Metabolism · doi:10.53941/hm.2025.100007 · Cited by 6
“Traditionally, glucose monitoring has relied on Self-Monitoring of Blood Glucose (SMBG) through finger-prick tests (Figure 1c) [9,10].”
Wang, Q., Zhou, Y., Wang, W., Ou, Y., Wu, X., Chen, J., Li, X., & Li, H. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1464071 · Cited by 9
Characterizing sleep in adults with Type 1 and Type 2 diabetes
Vézina‐Im, L., Turcotte, S., Turcotte, A., Beaulieu, D., Boudreau, F., & Morin, C. (2024) · Sleep Epidemiology · doi:10.1016/j.sleepe.2024.100078 · Cited by 9
Mancin, S., Zarrella, A., Petrelli, F., Cosmai, S., Cattani, D., Lopane, D., Scollo, S., Palomares, S. M., Sguanci, M. E., Amendola, A., et al. (2025) · Diabetology · doi:10.3390/diabetology6020010 · Cited by 9
Frías, J. P. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16593 · Cited by 6
“56,57 Several real-world studies have evaluated these outcomes in patients initiating FRC therapy.”
2. Glycaemic control assessment and targets in type 2 diabetes
Colagiuri, S., & Ceriello, A. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112146 · Cited by 9
Time in Range Is Closely Related to Healing Time of Diabetic Foot Ulcers
Ortiz-Zúñiga, Á., Simó‐Servat, O., Samaniego, J., Cuadra, F., Sánchez, M., Simó, R., & Hernández, C. (2025) · Wound Repair and Regeneration · doi:10.1111/wrr.70052 · Cited by 4
Application of Single-Atom Nanozymes in the Detection of Small Biomolecules: A Review
Zhang, W., Huang, R. Y., Luo, W. Y., et al. (2026) · Molecules · doi:10.3390/molecules31081242 · Cited by 4
“In diabetic patients, blood glucose concentrations persistently exceed the normal threshold (fasting blood glucose ≥ 7.0 mM), and dynamic monitoring of blood glucose fluctuation curves directly informs insulin dosage adjustment in treatment regimens [4].”
InfluentialSeidu, S. I., & Kunutsor, S. K. (2024) · Diabetes Care · doi:10.2337/dci24-0023 · Cited by 4
Self-citationHangaard, S., Kronborg, T., Cohen, S. R., Kofoed‐Enevoldsen, A., Thomsen, C. H. N., Aradóttir, T. B., Kristensen, S. N. S., Kaas, A., Bengtsson, H. L., Vestergaard, P., et al. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.05.017 · Cited by 9
Enhancing Type 2 Diabetes Care With CGM Integration: Insights From an Italian Expert Group
Irace, C., Avogaro, A., Bertuzzi, F., Buzzetti, R., Candido, R., Prato, S. D., Bartolo, P. D., Fiorina, P., Giorda, C. B., & Giorgino, F. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70059 · Cited by 7
An overview of the FreeStyle Libre monitoring system for individuals with type 1 and type 2 diabetes
Molfetta, S. D., Cutruzzolà, A., Gnasso, A., & Irace, C. (2025) · Expert Review of Medical Devices · doi:10.1080/17434440.2025.2489494 · Cited by 4
“Meta-analyses have demonstrated the efficacy of both rtCGM and isCGM in reducing the HbA1, minimizing the time spent in hypoglycemia, and improving TIR [15,72].”
Artificial intelligence for diabetes management – a review
Maheshwari, S., Kalia, A., Tewari, J., Tewari, A., Srivastava, A., Dantu, R., Sachan, A. K., Verma, N., & Maheshwari, A. (2025) · Journal of Diabetes Metabolic Disorders & Control · doi:10.15406/jdmdc.2025.12.00292 · Cited by 9
Artificial pancreas: the past and the future
Kitagawa, H., Munekage, M., Seo, S., & Hanazaki, K. (2025) · Journal of Artificial Organs · doi:10.1007/s10047-025-01510-1 · Cited by 9
“Compared with conventional self-monitoring of blood glucose, it not only reduces the burden on the patient [9] but also improves the time rate of achieving the target blood glucose range calculated from the continuous blood glucose levels measured with CGM (time in range; TIR).”
Aleppo, G. (2024) · Diabetes Care · doi:10.2337/dc24-0304 · Cited by 4
Tiano, S. M., Moczygemba, L. R., Hinds, A., Jokerst, J. R., Litten, K. P., Roscoe, C. A., & Sharma, R. (2025) · JAPhA Practice Innovations · doi:10.1016/j.japhpi.2025.100045 · Cited by 5
Diabetes and technology – an update for the general physician
Khin, K. L. S., Liarakos, A. L., IDRIS, I. R., Dhatariya, K., & Wilmot, E. G. (2025) · Clinical Medicine · doi:10.1016/j.clinme.2025.100539 · Cited by 3
Wilmot, E. G., Moore, P., Sathyapalan, T., Choudhary, P., Lim, J. Z. M., Neupane, S., Crabtree, T. S. J., Iqbal, A., Evans, M. L., Rayman, G. A., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00076-8 · Cited by 9
Self-citationHeer, R. S., Lovegrove, J., & Welsh, Z. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111950 · Cited by 6
Sebastián‐Valles, F., Jiménez‐Díaz, J., Ganga, C. S. L., Hierro, J. G., Enríquez, A. J., Barrena, A. S., Gamazo, J. P., Lobariñas, L. E. L., Tapia-Sanchiz, M. S., Carrera, M. A., et al. (2025) · Journal of Diabetes Research · doi:10.1155/jdr/5588397 · Cited by 5
“The of continuous and intermittently scanned glucose monitoring systems have extended beyond their 4 Journal of Diabetes Research initial indications in T1D [26], with growing evidence supporting their e ffi cacy in T2D [13].”
Savoy, A., Barboi, C., Thomas, M. R., & Weiner, M. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251369021 · Cited by 6
“25 As advancements in CGM become more accessible and available to older adults with type 2 diabetes, evaluating the use of CGM is critical for identifying barriers and facilitators for this population.”
Mayberry, L. S., Nelson, L. A., Bergner, E. M., Raymond, J. K., Tanenbaum, M. L., Jaser, S. S., Wiebe, D. J., Allen, N. A., Berg, C. A., Naranjo, D. M., et al. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241268560 · Cited by 3
Li, W., Weng, K., Wang, C., Zheng, D., & Li, X.-N. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.115568 · Cited by 1
Gong, M., Wu, Z., He, Y., Xiao, J., Men, X., & Chen, H. (2026) · Journal of Innovative Optical Health Sciences · doi:10.1142/s1793545826300053 · Cited by 5
Bruttomesso, D., Petrie, J. R., Evans, M. L., Fleming, G. A., Hanaire, H. P., Holl, R. W., Sherr, J. L., Bergenstal, R. M., Heinemann, L., & Peters, A. L. (2026) · Diabetologia · doi:10.1007/s00125-025-06651-9 · Cited by 3
Diabetes and metabolic disorders: Early identification and monitoring strategies
Goyat, J., Tiwari, B. K., & Sharma, R. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33263-0.00001-2 · Cited by 2
Digital Health Technologies for Cardiometabolic Disease and Diabetes
Warraich, H. J., Patrick‐Lake, B., Saha, A., Rashid, L., Pai, V. M., Abbasi, A., Diamond, M. C., Tazbaz, T., & Califf, R. M. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.10.075 · Cited by 2
Lu, L., Yin, X., Wang, C., Meng, X., Li, G., & Zhu, W. (2025) · Biological Research For Nursing · doi:10.1177/10998004251344888 · Cited by 2
“Continuous Glucose Monitoring (CGM) technology provides a more comprehensive glucose pro fi le by tracking blood glucose levels over an extended period (Seidu et al., 2024).”
Wallace, C., Rayan, M. N., Folk, S. Y. L., Harris, C., Faulds, E. R., GATTI, T., Duncan, P., Buschur, E., Wyne, K. L., Sobol, T., et al. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf169 · Cited by 3
Zhou, H., Wei, S., He, Y., Lin, Y., Deng, S., & Peng, C. (2025) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-025-01597-5 · Cited by 1
Sebastian, S. A., Padda, I., Bimal, T., Varma, S., Collins, J. S. P., Ahmad, Z., & Safarova, M. S. (2025) · Disease-a-Month · doi:10.1016/j.disamonth.2025.102043 · Cited by 3
Tan, J. C., Khalil, M. A. M., Avari, P., & Leelarathna, L. (2025) · Frontiers in Nephrology · doi:10.3389/fneph.2025.1630597 · Cited by 1
Lim, S. K., Nishimura, R., Kesavadev, J., Kong, A. P. S., McGill, M. J., Ou, H., Chun Kwan, O., Lee, C., Zhang, X., Ji, L., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.113054 · Cited by 1
Son, H., Moon, S. J., & Cho, Y. M. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01830-8 · Cited by 7
“Time in range (TIR), defined as the percentage of time glucose levels remain within the target range of 70–180 mg/dl (3.9–10 mmol/l), increased significantly among isCGM users and non‑sig‑ nificantly among rtCGM users [15].”
InfluentialLian, X., Cheng, L. J., Teo, C. J. Y., Tan, J., Lim, H., Shen, L., Chew, H. S. J., Wang, W., & Dalan, R. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1761579 · Cited by 1
Addressing barriers to CGM prescriptions in primary care: a quality improvement initiative
Yoo, A., Cherayil, N. A., ROSADO, R. M. S., & Rubin, A. (2026) · BMJ Open Quality · doi:10.1136/bmjoq-2025-003654 · Cited by 1
Luo, N., Feng, S., Chen, H., She, D., Liu, Y. S., Li, Y., Yan, C. X., Zhang, Z., Chen, J., Cai, X.-L., et al. (2026) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.70221 · Cited by 1
Pal, A. W., Chong, W. L., Huri, H. Z., & Ratnasingam, J. (2026) · Diabetic Medicine · doi:10.1111/dme.70360 · Cited by 1
Villanueva, G. P., Solorzano, W. M., & Everett, E. M. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01631-8 · Cited by 2
“Improvements in diabetes-specific quality of life have also been reported [ 21 ] and meta-analysis data further indicate that intermittently scanned CGM use is associated with higher user satisfaction compared to SMBG [7].”
InfluentialImpact of Hybrid Continuous Glucose Monitoring on Glycemic Control in a Medical Intensive Care Unit
Faulds, E. R., Rayan, M. N., McNett, M., Exline, M. C., JONES, L. G., Shoben, A. B., Lin, C. J., Lee, B., Rasul, A., & Dungan, K. M. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.08.021 · Cited by 1
Štechová, K., Kovács, R., Tuháčková, M., Salátová, M., Malá, Š., Piťhová, P., & Pichlerová, D. (2024) · Kontakt · doi:10.32725/kont.2024.028 · Cited by 1
“There are already many studies (international and national) that demonstrate the clinical benefit of using glucose sensors even in patients with other types of diabetes (Radovnická et al., 2022; Seidu et al., 2024).”
Davidson, M. B., & Davidson, S. J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15679 · Cited by 1
Kim, J. Y., Ilham, S., Alshannaq, H. A., Pollock, R. F., Field, M., Norman, G. J., Jin, S., & Kim, J. H. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251382570 · Cited by 2
Kargbo, R. B. (2024) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00329 · Cited by 1
Continuous and Intermittent Glucose Monitoring in 2024
Dovč, K., Bode, B. W., & Battelino, T. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.8802.kd · Cited by 2
Xu, W., Sakal, C., Zhang, W., Chen, T., Wang, C., Zhao, Q., & Li, X. (2025) · medRxiv · doi:10.1101/2025.07.26.25332240 · Cited by 1
“Continuous glucose monitoring (CGM) has demonstrated its effectiveness in diabetes management (11, 12), offering a powerful tool to overcome the limitations of traditional glycemic biomarkers.”
Lameijer, A. (2024) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.1021051970
Okuno, K., Niihara, M., Fujita, S., Higuchi, T., Harada, H., Washio, M., Sakuraya, M., Kumagai, K., Sato, T., Sangai, T., et al. (2025) · Surgical Case Reports · doi:10.70352/scrj.cr.24-0099
“17) Maintaining blood glucose levels within an appropriate range is crucial to prevent adverse events and improve patient outcomes.”
Primary Care and Diabetes Technologies and Treatments
Simonson, G. D., Martens, T. W., Carlson, A. L., & Bergenstal, R. M. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.8810.gds
Kaya, A. (2025) · Medical Records · doi:10.37990/medr.1645581
Gated Recurrent Unit for Diabetes Prediction in Voice Data
Patidar, P. K., Shiwani, S., & Garg, S. (2025) · International Conference on Recent Advances in Information Technology · doi:10.1109/rait65068.2025.11089095
“In people with T2D, both CGM and isCGM showed a decrease in HbA1c levels; however, the use of isCGM was linked to higher user satisfaction than CGM [18].”
Adaptive personalization for wearable non-invasive continuous glucose sensors
Yao, C., Yao, C., Huang, X., Wang, X., Huang, S., Li, G., Han, X., Yang, H., Liu, Z., Liang, S., et al. (2026) · Nature Communications · doi:10.21203/rs.3.rs-7477881/v1
An Apple-watch all day keeps your life astray—or does it?
Meland, E. (2025) · Scandinavian Journal of Public Health · doi:10.1177/14034948251370466
“For example, some new glucose-monitoring tools helped control blood sugar but also increased the risk of side effects [5].”
Jensen, M. K., & Bjerre, N. (2025) · JMIR Research Protocols · doi:10.2196/69852
“[37-42] Initial: continuous glucose monitoring sensors will provide the target group with real-time blood glucose level data.”
Yamamoto‐Kataoka, S., Tsuge, T., Kataoka, Y., Metzendorf, M., Franco, J. V. A., & Watanabe, N. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016111
Validity and Reliability of the Turkish Version of the Glucose Monitoring Satisfaction Survey
Bilgehan, T., & Toygar, İ. (2025) · Hitit Medical Journal · doi:10.52827/hititmedj.1704087 · Cited by 1
Continuous Glucose Monitoring: A Practical Overview for Primary Care Providers in Canada
Shin, S., & Gilbert, J. D. (2025) · Canadian Primary Care Today · doi:10.58931/cpct.2025.3349
“7 These complications may lead to premature sensor removal or discontinuation of CGM. Strategies to mitigate these effects include cleansing the skin with alcohol, ensuring the site is completely dry prior to sensor placement, applying a topical corticosteroid (e.g., fluticasone) before insertion,…”
Chou, Y.-Y., Liu, F.-H., & Lin, C. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-02108-7
“In adults with poorly-controlled type 2 diabetes, CGM leads to significantly lower HbA1c levels and improves glucose control compared with regular blood glucose monitoring (BGM) [13–15].”
Scoping review of subcutaneous glucose monitoring techniques
Hrubá, E., Kubíček, J., & Augustýnek, M. (2025) · Measurement · doi:10.1016/j.measurement.2025.119940 · Cited by 1
Nowacka, K., Grygorowicz, A., Baran, K., Ględa, M., Szyszka, M., Radecka, W., Kozak, W., Szreiber, A., Grela, K., Jabłoński, K., et al. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4660
Foo, N., Chodapaneedi, S., Gibson, B. N., Koh, H. J. W., Gašević, D., Hamblin, P. S., Trin, C., Cataldo-Miranda, P., Zomer, E., Russell, A. W., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70401
“In our review, several included studies reported only aggregated effects for CGM, 10,11,25,27 – 29 without stratifying by monitoring type.”
InfluentialDwiastuti, A., Latarissa, I. R., Hidayat, A., Halimah, E., & Lestari, K. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s561759 · Cited by 2
“Future research should focus on long-term studies, use of diabetes-specific QoL instruments, and inclusion of behavioral, economic, and equity-related outcomes to provide a more comprehensive understanding of CGM’s role in T2DM care.”
Severe Hypoglycemia in Insulin-Treated Type 2 Diabetes: A Call to Revisit Diabetes Education
Bilal, A., Osorio, S., & Casu, A. (2026) · Diabetes Care · doi:10.2337/dci25-0117 · Cited by 2
Deng, G., & Chengshi, W. (2026) · Science Progress · doi:10.1177/00368504261418899 · Cited by 1
Benefits and Barriers to Use of CGM 24 Weeks Following Hospital Discharge.
Rayan, M. N., Wallace, C. R., Folk, S., Cnp, C. H., Faulds, E., Gatti, T., Duncan, P., Buschur, E., Sobol, T., Wyne, K., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.02.013
Accuracy and performance of the Yuwell Anytime CT3 continuous glucose monitoring device
Lancaster, M. K., Edwards, H., Harper, D., Garner, P., & Utley, A. (2026) · British Journal of Nursing · doi:10.12968/bjon.2026.0009
Letter to the Editor: ‘Diabetes and technology – an update for the general physician’
Udmale, P. M., Khobragade, V. R., & Dixit, A. (2026) · Clinical Medicine · doi:10.1016/j.clinme.2026.100578
Watada, H., Tanaka, S., Matuoka, J. Y., Alshannaq, H. A., Pollock, R. F., Field, M., & Norman, G. J. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70279
Fluit, R. C., van der Bie, S., van den Akker, J. P. C., van Lelyveld, S. F. L., Short, K. R., Stads, S., Spronk, P. E., Bethlehem, C., Takken, R., den Uil, C. A., et al. (2026) · BMC Infectious Diseases · doi:10.1186/s12879-026-13221-w
Hayek, A. A., Zahrani, W. M. A., Alotaibi, H. F., Saleh, J. Y., & Dawish, M. A. A. (2026) · Primary care diabetes · doi:10.1016/j.pcd.2026.04.002 · Cited by 1
Talaiti, M., Liao, X., Abulimiti, N., Zeng, M., & Wang, Y. (2026) · Journal of Diabetes Research · doi:10.1155/jdr/1464982
Okada, H., Suzuki, S., Domichi, M., & Sakane, N. (2026) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2026.04.005
Kesavadev, J., Toh, S. A., Kong, A. P.-S., McGill, M. J., Ashik, A., Lee, M. H., Chun Kwan, O., & Twigg, S. M. (2026) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_40_25 · Cited by 1
Pharmacy Student Confidence and Practice Readiness After Diabetes Educational Module With CGM Use
Hursman, A., Monson, E., Luthi, A., et al. (2026) · Journal of Pharmacy Technology · doi:10.1177/87551225261433431
Freedom through technology: transforming management of type 2 diabetes
Boughton, C. K. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00080-x
Metadata
- Authors
- Seidu, S., Kunutsor, S. K., Ajjan, R. A., & Choudhary, P.
- Affiliations
- University of Leicester (GB)
- University of Leeds (GB)
- Corresponding author
- Seidu, Samuel
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2023-12-20
- Volume
- 47
- Issue
- 1
- Pages
- 169-179
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4389988073
- Cited by
- 124
- References
- 29
- Citations by year
- 2026: 50 · 2025: 57 · 2024: 17
- FWCI
- 4.45
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- NIHR Leicester Biomedical Research Centre
- National Institute for Health Research
- Applied Research Collaboration East Midlands
- ARC
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- continuous glucose monitoring, intermittently scanned continuous glucose monitoring, type 2 diabetes, glycemic control, HbA1c, self-monitoring of blood glucose, user satisfaction, adverse events, body composition, blood pressure, serum lipids, diabetes self-management
- MeSH terms
- Continuous Glucose Monitoring, Adult, Blood Glucose, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Lipids, Blood Glucose Self-Monitoring
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.